Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what alternatives will be available for the third line of treatment for patients with gastrointestinal stromal tumours as a result of the review of treatments under the Cancer Drug Fund.

Regorafenib for the treatment of previously treated gastrointestinal stromal tumours is due to be removed from the Cancer Drugs Fund (CDF) Drugs list for new patients on 12 March 2015. The rationale for the CDF panel’s decision has been published, and overall the panel’s conclusion was that this drug offered insufficient value for retention within the CDF. Approximately 74 patients a year would access this drug in this indication and it is recognised that many of these patients may not have any further active anti-cancer drug treatment options and therefore will be offered best supportive care through their multi-disciplinary cancer team.